# OnCo record rasolute-302 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/rasolute-302/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "rasolute-302", "NCT06625320" ;
  schema:name "RASolute 302"@en ;
  schema:description "The trial that nearly doubled survival in previously treated pancreatic cancer, presented in the ASCO 2026 plenary. The biggest result in the disease's history."@en ;
  schema:url <https://onco.cc/trials/rasolute-302/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06625320>, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma>, <https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit>, <https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA5>, <https://doi.org/10.1056/NEJMoa2605555>, <https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22RASONQUE%22> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2024-10-16" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/daraxonrasib/> ;
  onco:companies <https://onco.cc/companies/revolution-medicines/> ;
  onco:institutions <https://onco.cc/institutions/dana-farber/> ;
  onco:trials <https://onco.cc/trials/nct07491445/>, <https://onco.cc/trials/nct07252232/>, <https://onco.cc/trials/codebreak-100/>, <https://onco.cc/trials/napoli-1/>, <https://onco.cc/trials/conko-003/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-bournet-kras-g12d-prognosis-pancreatic-ctg-2016/> .